Mary‐Elizabeth M. Percival

Also affiliated with Fred Hutch Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies”.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3706

N/A

4.4DataRank · unranked

198 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility

Haematologica(2020)10.3324/haematol.2020.254938

N/A

0DataRank · unranked

5 citations

Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern +6 more

A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7007

N/A

0DataRank · unranked

1 citations

Kim Quach, Ted Gooley, Christen H. Martino, Sindhu Cherian, Mary‐Elizabeth M. Percival +8 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017.v1

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Time independent factors that predict relapse in adults with acute myeloid leukemia

Blood Cancer Journal(2024)10.1038/s41408-023-00954-z

N/A

0DataRank · unranked

8 citations

Megan Othus, Carole Shaw, Kathryn Russell, Anna B. Halpern, Jacob Appelbaum +5 more

Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samples

npj Biofilms and Microbiomes(2025)10.1038/s41522-025-00725-7

N/A

0DataRank · unranked

5 citations

Hakan Gem, Kevin K. Chung, Jeffrey S. McLean, Kristopher A. Kerns, Meredith A.J. Hullar +10 more

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

Blood Neoplasia(2025)10.1016/j.bneo.2025.100129

N/A

0DataRank · unranked

0 citations

Megan Othus, Mary‐Elizabeth M. Percival, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba +2 more

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood Advances(2020)10.1182/bloodadvances.2019000707

N/A

0DataRank · unranked

28 citations

Kelda M. Gardner, Kathleen Shannon Dorcy, Andrea Perdue, Heather Smith, Alicyn M. Davis +12 more

National Landscape of Logistical and Nonmedical Requirements for Transplantation and Cellular Therapy

Transplantation and Cellular Therapy(2025)10.1016/j.jtct.2025.10.031

N/A

0DataRank · unranked

0 citations

Helene Starks, Lindsey Bandini, T. Harrington, Mary‐Elizabeth M. Percival, Roland B. Walter +6 more